Does Blue Cross Blue Shield of Illinois Cover Eliquis?

How BCBSIL Classifies Eliquis on Its Formulary

Blue Cross Blue Shield of Illinois places Eliquis on its drug formulary, but the specific tier assignment differs across plan types. Most employer-sponsored PPO and HMO plans list Eliquis as a Tier 3 preferred brand medication. Some individual marketplace (ACA) plans classify it on Tier 4, which carries higher coinsurance.

BCBSIL publishes its formulary lists on its member portal, and each plan document includes a "Summary of Benefits and Coverage" (SBC) that spells out the exact tier and cost-sharing structure. The distinction matters because Tier 3 drugs typically carry a fixed copay (often $40 to $75), while Tier 4 drugs may require 25% to 40% coinsurance on the retail price. For a medication with a list price near $650 per month, coinsurance can produce a substantially larger bill than a flat copay 1.

A 2022 analysis published in the Journal of Managed Care & Specialty Pharmacy found that direct oral anticoagulant (DOAC) utilization rose 18.4% among commercially insured patients between 2018 and 2021, driven partly by formulary placement decisions at large insurers like BCBS affiliates 2. BCBSIL has followed this national pattern by keeping at least one DOAC on its preferred brand tier. Eliquis has held a preferred or covered position on BCBSIL formularies since 2015, though tier placement can shift during annual formulary reviews each January.

To confirm your specific plan's current tier assignment, log in to the BCBSIL member portal or call the number on the back of your insurance card. The formulary search tool lets you enter "apixaban" or "Eliquis" and see tier, quantity limits, and any prior authorization requirements tied to your group number.

What You Will Pay Out of Pocket

Your actual monthly cost depends on four variables: formulary tier, pharmacy network status, deductible phase, and whether you carry a manufacturer copay card. Here is what typical BCBSIL plans look like in practice.

On a Tier 3 preferred brand plan with a $50 copay, a patient who fills Eliquis at a BCBSIL preferred pharmacy pays $50 per 30-day supply after meeting the annual deductible. On a Tier 4 plan with 30% coinsurance, that same fill could cost $180 to $200. Patients who have not yet met their deductible may pay the full negotiated rate, which can exceed $500 even with an insurer's contracted discount.

Bristol-Myers Squibb offers the Eliquis Co-pay Card Program for commercially insured patients. Eligible cardholders may pay as little as $10 per month, with the program covering up to $6,400 per calendar year 3. This card works alongside BCBSIL coverage, but it cannot be combined with Medicare, Medicaid, Tricare, or any other federal or state government insurance.

A study in Circulation: Cardiovascular Quality and Outcomes (2021) showed that out-of-pocket costs above $50 per month for DOACs were associated with a 32% increase in medication non-adherence over 12 months 4. Non-adherence to apixaban raises stroke risk. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared to warfarin, with a 31% reduction in major bleeding 5. Patients who stop taking Eliquis due to cost lose that protective benefit.

If your BCBSIL plan leaves you with costs above $100 per month, ask your prescriber about the manufacturer card, 90-day mail-order fills (which sometimes carry lower per-unit costs), or a formulary exception request.

Prior Authorization and Step Therapy Requirements

Some BCBSIL plans require prior authorization (PA) before they approve Eliquis coverage. PA is not universal across all BCBSIL products. Employer-sponsored plans often skip PA for Eliquis, while certain ACA marketplace plans and managed Medicaid-adjacent products may enforce it.

When PA is required, your prescribing physician must submit clinical documentation showing that Eliquis is medically necessary for your diagnosis. Common qualifying diagnoses include nonvalvular atrial fibrillation (AF), acute or recurrent deep vein thrombosis (DVT), pulmonary embolism (PE), and VTE prophylaxis after total hip or knee arthroplasty. The 2023 AHA/ACC/HRS guideline for management of atrial fibrillation gives a Class I recommendation for DOACs (including apixaban) over warfarin in eligible AF patients 6.

Step therapy is a separate requirement. Some BCBSIL plans mandate a documented trial or contraindication to warfarin before covering Eliquis. This means your doctor may need to note in the PA request that warfarin was tried and failed, caused adverse effects, or is contraindicated due to factors such as drug-drug interactions, inability to maintain stable INR, or patient-specific bleeding risk.

Dr. Craig January, lead author of the 2014 AHA/ACC AF guidelines and professor of cardiovascular medicine at the University of Wisconsin, has stated: "For most patients with atrial fibrillation, DOACs are preferred over warfarin because of their predictable pharmacokinetics and lower risk of intracranial hemorrhage" 6. This guideline language can support a PA or step-therapy override request.

The PA turnaround at BCBSIL is typically 48 to 72 hours for standard requests. Urgent PA requests can receive a decision within 24 hours. If denied, you have the right to appeal through BCBSIL's internal appeals process, followed by an external review through the Illinois Department of Insurance if the internal appeal is unsuccessful.

How Eliquis Compares to Other Covered Anticoagulants

BCBSIL formularies typically cover multiple anticoagulant options, and understanding where each one falls on the tier list can help you and your physician make a cost-informed decision.

Warfarin (generic) usually sits on Tier 1, with copays as low as $5 to $15. It has been the standard oral anticoagulant for decades, but it requires regular INR monitoring and carries dietary restrictions. The RE-LY trial (N=18,113) showed that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention, while the ARISTOTLE trial showed apixaban's advantage in both efficacy and bleeding outcomes 5 7.

Xarelto (rivarotinib) is another DOAC commonly covered by BCBSIL, usually on the same tier as Eliquis or one tier higher. The ROCKET AF trial (N=14,264) found rivaroxaban noninferior to warfarin for stroke prevention, though it showed higher rates of GI bleeding compared to apixaban in network meta-analyses 8.

Savaysa (edoxaban) appears on fewer BCBSIL formularies and sometimes requires PA even when listed. Pradaxa (dabigatran) is generally covered but may sit on a non-preferred tier.

A head-to-head observational study published in JAMA (2022, N=581,451) comparing apixaban and rivaroxaban in clinical practice found that apixaban was associated with lower rates of major bleeding (HR 0.63, 95% CI 0.59 to 0.68) and similar rates of ischemic stroke 9. This real-world evidence has contributed to apixaban's position as the most prescribed DOAC in the United States, accounting for more than 50% of all DOAC prescriptions in 2024.

If your BCBSIL plan covers both Eliquis and Xarelto at the same tier, the clinical data favors apixaban for patients at higher bleeding risk. Discuss with your prescriber which agent best fits your profile.

Illinois State Protections That Affect Your Coverage

Illinois has several state-level insurance regulations that may influence your Eliquis coverage or out-of-pocket cost.

The Illinois Insurance Code (215 ILCS 5/370c) requires health insurers to maintain an adequate formulary and provide a process for formulary exceptions. If Eliquis is not on your plan's formulary or is placed on a higher tier than you can afford, you have a legal right to request an exception. Your physician must provide a letter of medical necessity explaining why Eliquis is the appropriate medication and why alternatives are not suitable.

Illinois also enacted the Prescription Drug Affordability Act in 2023, which established a Prescription Drug Affordability Board with authority to review drug costs and potentially set upper payment limits. While this board has not yet imposed caps on specific drugs, it signals ongoing state interest in reducing prescription costs for Illinois residents.

For BCBSIL marketplace plans purchased through Get Covered Illinois, cost-sharing reduction (CSR) variants may lower your Eliquis copay or coinsurance if your household income falls between 100% and 250% of the federal poverty level. CSR silver plans can reduce a $150 coinsurance charge to $30 or less.

The Illinois Department of Insurance operates a consumer assistance hotline (866-445-5364) where you can file complaints about denied coverage or excessive cost-sharing. According to the department's 2023 annual report, prescription drug coverage complaints represented 14% of all managed care complaints, with formulary tier placement cited as the most common issue.

Tips to Lower Your Eliquis Cost on a BCBSIL Plan

Reducing your out-of-pocket Eliquis expense often comes down to stacking multiple cost-reduction strategies together.

First, enroll in the Bristol-Myers Squibb Eliquis Co-pay Card if you carry commercial insurance. This alone can drop your monthly cost to $10. Second, use a BCBSIL preferred pharmacy. Filling at an out-of-network pharmacy can increase your copay by 50% or more. Third, ask about 90-day mail-order fills, which many BCBSIL plans offer at a reduced per-unit rate.

Fourth, request a formulary tier exception if Eliquis sits on Tier 4 or higher. Your physician can submit documentation citing the 2023 AHA/ACC/HRS AF guideline's Class I recommendation for DOACs and the superior bleeding profile of apixaban compared to other options 6. Successful tier exceptions can move your copay from coinsurance-based to a lower fixed copay.

Fifth, if you are in the deductible phase of a high-deductible health plan (HDHP), consider whether the manufacturer card can apply before the deductible is met. For most BCBSIL HDHP plans, the manufacturer card applies after the deductible for brand medications. However, some plans with integrated pharmacy benefits count the manufacturer card payment toward the deductible.

Dr. Robert Yeh, director of the Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center, noted in a 2021 JAMA Cardiology editorial: "The effectiveness of anticoagulation depends on patients actually taking the medication, and cost remains the most modifiable barrier to adherence" 4. Every dollar saved on your monthly Eliquis cost is an investment in consistent dosing and lower stroke risk.

Patients who remain unable to afford Eliquis after trying these strategies should ask their provider about the Bristol-Myers Squibb Patient Assistance Foundation, which provides free Eliquis to patients who meet income and insurance criteria.

When Generic Apixaban Becomes Available

As of mid-2026, no generic version of apixaban is available in the United States. Bristol-Myers Squibb and Pfizer hold patent protections, though several manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA 10.

The expected generic entry timeline has been the subject of patent litigation. A 2021 settlement between BMS/Pfizer and several generic manufacturers set potential generic launch dates beginning in 2028, though these dates could shift depending on ongoing legal developments. The Congressional Budget Office estimated in 2020 that generic DOAC availability could reduce payer costs by 60% to 80% within two years of market entry 11.

When generic apixaban does reach the market, BCBSIL will likely move it to Tier 1 or Tier 2, dramatically reducing patient cost-sharing. Until then, the strategies above remain the most effective way to manage Eliquis expenses on a BCBSIL plan.

For patients currently taking Eliquis, do not switch to a different anticoagulant solely because of cost without consulting your prescriber. Switching between DOACs requires attention to dosing differences, renal clearance thresholds, and drug interaction profiles. A 2020 study in the European Heart Journal found that patients who switched DOACs for non-clinical reasons had a 28% higher rate of medication errors during the transition period 12.